Interleukin Genetics has received approval from the State of New York's Department of Health to sell its PST Genetic Test in New York.
The test, which has been available in all other U.S. states, is used to determine predisposition to severe periodontal disease in individuals. It is the only genetic test available that is capable of identifying which patients are at increased risk for developing severe periodontal disease, according to the company. The test is especially useful in patients with early signs of periodontal disease, including recurrent gingivitis and early-to-moderate periodontitis, to identify those more likely to develop severe periodontitis and associated complications.
Interleukin Genetics currently distributes its PST genetic test to dentists through a licensing agreement with OralDNA Labs, a subsidiary of Quest Diagnostics.
